Compounds > e-ebu-dm
Page last updated: 2024-11-08

e-ebu-dm

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID453151
CHEMBL ID310976
SCHEMBL ID2107018
MeSH IDM0290600

Synonyms (15)

Synonym
CHEMBL310976 ,
6-(3,5-dimethylbenzyl)-1-ethoxymethyl-5-ethyl-1,2,3,4-tetrahydro-2,4-pyrimidine dione
6-(3,5-dimethyl-benzyl)-1-ethoxymethyl-5-ethyl-1h-pyrimidine-2,4-dione
bdbm50032235
6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethyl-pyrimidine-2,4-dione
136160-30-0
5-ethyl-1-ethoxymethyl-6-(3,5-dimethylbenzyl)uracil
e-ebu-dm
2,4(1h,3h)-pyrimidinedione, 6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethyl-
6-[(3,5-dimethylphenyl)methyl]-1-(ethoxymethyl)-5-ethylpyrimidine-2,4-dione
1-ethoxymethyl-5-ethyl-6-(3,5-dimethylbenzyl)uracil
2,4(1h,3h)-pyrimidinedione, 6-((3,5-dimethylphenyl)methyl)-1-(ethoxymethyl)-5-ethyl-
SCHEMBL2107018
DTXSID00159709
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-ethylpyrimidine-2,4(1h,3h)-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1EC50 (µMol)0.00160.00040.61539.7000AID200009
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID105530Effective dose of compound required to inhibit 50% of HIV-1 antigen production in MT-4 cultures.1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID104945Cytotoxic dose required to reduce the proliferation of normal uninfected MT-4 cells1996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID46051Tested for inhibitory concentration on HIV-I Lai wild type in CEM-SS cell line2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID104938Cytotoxic concentration required to reduce the viability of mock-infected MT-4 cells by 50%1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID235484Selectivity index is the ratio of CC50 to IC502000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID235474Selectivity index is the ratio between CD50 and ED501996Journal of medicinal chemistry, Jun-07, Volume: 39, Issue:12
Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.
AID45180Tested for cytotoxic concentration on HIV-I Lai wild type in CEM-SS cell line2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID105513Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1 virus.1995Journal of medicinal chemistry, Jul-21, Volume: 38, Issue:15
Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents.
AID200009Inhibitory concentration against HIV-1 reverse transcriptase1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
A 3D QSAR study of a series of HEPT analogues: the influence of conformational mobility on HIV-1 reverse transcriptase inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's1 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
uracil
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder		1.9910pyrimidine nucleobase;
pyrimidone		allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil
6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil: an anti-HIV agent; structure in first source. 6-(3,5-dimethylbenzyl)-1-(ethoxymethyl)-5-isopropyluracil : A pyrimidone that is uracil which is substituted at positions 1, 5, and 6 by ethoxymethyl, isopropyl, and 3,5-dimethylbenzyl groups, respectively.		2.6830pyrimidone
nevirapine
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.		2.420cyclopropanes;
dipyridodiazepine		antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil
1-(ethoxymethyl)-5-isopropyl-6-(phenylsulfanyl)uracil : A pyrimidone that is uracil in which positions 1, 5, and 6 are substituted by ethoxymethyl, isopropyl, and phenylsulfanyl groups, respectively.		1.9910aryl sulfide;
pyrimidone
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.6830azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
1-((2-hydroxyethoxy)methyl)-6-(phenylthio)thymine
1-[(2-hydroxyethoxy)methyl]-6-(phenylsulfanyl)thymine : A pyrimidone that is thymine which is substituted at positions 1 and 6 by a (2-hydroxyethoxy)methyl group and a phenylsulfanyl group, respectively.		1.9810aryl sulfide;
primary alcohol;
pyrimidone		antiviral drug;
HIV-1 reverse transcriptase inhibitor
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil
5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil: inhibits human HIV-1; structure given in first source		1.9910
emivirine
emivirine: a non-nucleoside inhibitor of HIV-1 reverse transcriptase. emivirine : A pyrimidone that is uracil which is substituted at positions 1, 5 and 6 by ethoxymethyl, isopropyl, and benzyl groups, respectively. A non-nucleoside inhibitor of HIV-1 reverse transcriptase, emivirine was an unsuccessful experimental agent for the treatment of HIV.		2.6830pyrimidoneantiviral drug;
HIV-1 reverse transcriptase inhibitor
5-ethyl-1-benzyloxymethyl-6-(phenylthio)uracil
[no description available]		1.9910
3-dimethylamino-4-(3,5-dimethylbenzyl)-5-ethyl-6-methylpyridin-2(1h)-one
3-dimethylamino-4-(3,5-dimethylbenzyl)-5-ethyl-6-methylpyridin-2(1H)-one: structure in first source		210
r-82913
R-82913: antiviral target on reverse transcriptase of HIV-1		2.420
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		01.9810
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		01.9810